Other
PT-141 Dosage, Protocol & Research Guide
Label figures describe the approved branded products. The research materials listed on this page are not approved drugs and are not evaluated by any regulator.
- MW 1,025.2 g/mol
- CAS 189691-06-3
Dose overview
Every range below is taken from the cited source and carries its evidence grade.
Label figures describe the approved branded products. The research materials listed on this page are not approved drugs and are not evaluated by any regulator.
Human data and community reports
| Source | Population | Dose | Frequency | Route | Duration | Evidence |
|---|---|---|---|---|---|---|
| Vyleesi (bremelanotide) US label (DailyMed)[1]1.75 mg administered subcutaneously in the abdomen or thigh as needed at least 45 minutes before anticipated sexual activity; label states no more than one dose within 24 hours and a limit of 8 doses per month | humanpremenopausal women with acquired, generalized hypoactive sexual desire disorder (labelled indication) | 1.75 mg[1]subcutaneous, labelled dose per use, as needed; not a daily schedule | as needed; no more than one dose within 24 hours | subcutaneous | — | Approved product label |
Evidence grades: A approved label, B human trial, C observational, D animal study, E community-reported.
Reconstitution calculator
- Concentration
- 5 mg/mL
- Volume to draw
- 0.05 mL
- Units on a U-100 syringe
- 5 units
- Draws per vial
- 40
Properties
- CAS
- 189691-06-3
- Molecular weight
- 1,025.2 g/mol
- Formula
- Not yet recorded
- Sequence
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Aliases
- Bremelanotide, Vyleesi, PT141
- Vial sizes (mg)
- 10
Storage notes
- Lyophilized
- Not yet recorded from a cited source
- Reconstituted stability (days)
- Not yet recorded from a cited source
Side effects, contraindications and regulatory status
Reported side effects
- Warnings and Precautions: transient increase in blood pressure and decrease in heart rate occurs after each dose and usually resolves within 12 hours (Vyleesi label).[1] Approved label
- Nausea was reported by 40.0% of Vyleesi users versus 1.3% on placebo (label Table 1); the warnings section says nausea was reported by 40% of those given up to 8 monthly doses.[1] Approved label
- Other adverse reactions in label Table 1 (Vyleesi vs placebo): flushing 20.3% vs 0.3%; injection site reactions 13.2% vs 8.4%; headache 11.3% vs 1.9%.[1] Approved label
- Focal hyperpigmentation was reported by 1% of those who received up to 8 doses per month, including involvement of the face, gingiva and breasts (Vyleesi label, Warnings and Precautions).[1] Approved label
- Label section 8.1: advise discontinuing Vyleesi if pregnancy is suspected; section 8.2: no information on the presence of bremelanotide or its metabolites in human milk.[1] Approved label
Contraindications
- Uncontrolled hypertension or known cardiovascular disease (Vyleesi label, Contraindications).[1] Approved label
Regulatory status
US label (DailyMed) for Vyleesi (bremelanotide): premenopausal women with acquired, generalized HSDD; Initial U.S. Approval 2019. Checked 2026-10-20.[1] Source
Report any adverse reaction to a qualified healthcare professional.
What the research says
Summaries of the cited studies, each with its evidence grade.
Vyleesi (bremelanotide) US label (DailyMed)[1]
Vyleesi (bremelanotide) US label (DailyMed): 1.75 mg administered subcutaneously in the abdomen or thigh as needed at least 45 minutes before anticipated sexual activity; label states no more than one dose within 24 hours and a limit of 8 doses per month
Compare vial sizes
| Size | Price | Doses available from the vial Calculated | Cost per dose Calculated |
|---|---|---|---|
| 10 mg | $58.99 | 5 | $11.80 |
Cost per dose uses the listed partner price and the reference dose cited on this page. Prices change; check the product page.
Calculated from a default of 2 mL water (adjustable).
PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.
Frequently asked questions
What dose figures are published for PT-141?
Cited figures on this page: 1.75 mg as needed; no more than one dose within 24 hours, subcutaneous, labelled dose per use, as needed; not a daily schedule [1] (Approved product label, evidence grade A). These are summaries of published sources, not medical advice. Each figure links to its source in the references.
What is the regulatory status of PT-141?
US label (DailyMed) for Vyleesi (bremelanotide): premenopausal women with acquired, generalized HSDD; Initial U.S. Approval 2019. Checked 2026-10-20.
Compound facts
What is the molecular weight of PT-141?
What is the CAS number of PT-141?
How is PT-141 stored in the laboratory?
References
Numbered sources used on this page. Markers in the text link here.
- Vyleesi (bremelanotide) US label (DailyMed) dailymed.nlm.nih.gov Approved label
Vial sizes and protocols
10 mgPartner size
- Doses per vial
- 5
Calculated from a default of 2 mL water (adjustable).
Available from Pepcore
Supplied as research material for laboratory use only.
Label figures describe the approved branded products. The research materials listed on this page are not approved drugs and are not evaluated by any regulator.
- Shop at PepcoreCoupon code
LAUNCH20
PeptideCheck may earn a commission when you use Pepcore links, at no extra cost to you. Read the disclosure.